Limitations of Lymph Node Counts as a Measure of Therapy

Authors:
Scott M. GilbertFrom the Departments of Urology and Epidemiology and Health Policy Research, University of Florida, Gainesville, Florida, and Divisions of Health Services Research and Urologic Oncology, Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan.

Search for other papers by Scott M. Gilbert in
Current site
Google Scholar
PubMed
Close
 MD, MS
and
Brent K. HollenbeckFrom the Departments of Urology and Epidemiology and Health Policy Research, University of Florida, Gainesville, Florida, and Divisions of Health Services Research and Urologic Oncology, Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan.

Search for other papers by Brent K. Hollenbeck in
Current site
Google Scholar
PubMed
Close
 MD, MS
Full access

For several cancers, the number of lymph nodes removed during surgery is associated with survival. Observational studies supporting this association have prompted considerable debate regarding the extent of lymphadenectomy, and in some dieases, absolute lymph node counts have been suggested as a measure of the quality of cancer care. However, for most cancers, lymph node counts may not directly influence survival in a causal manner. In fact, several randomized clinical trials addressing the question in lung, gastric, and pancreatic cancers have not shown more extensive lymph node dissections to be linked with improved survival. Despite this negative evidence, however, lymph node counts have remained a target process in quality initiatives. Misinterpretation of the evidence may be driving some of the pressure to broadly implement more extended lymph node dissections. As a process for more accurate disease staging and as a potential marker for the completeness of surgery, lymph node counts are likely linked to quality, at least indirectly. However, a causal association between lymph node counts (and extented lymphadenectomy) and survival is tenuous and has not been supported by high-level evidence.

Correspondence: Scott M. Gilbert, MD, MS, Department of Urology College of Medicine, University of Florida, 1600 SW Archer Road, N202, Gainesville, FL 32610. E-mail: Scott.Gilbert@urology.ufl.edu
  • Collapse
  • Expand
  • 1

    Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005;23:71147124.

    • Search Google Scholar
    • Export Citation
  • 2

    Chang GJ, Rodriguez-Bigas MA, Skibber JM et al.. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99:433441.

    • Search Google Scholar
    • Export Citation
  • 3

    Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program database. J Urol 2003;169:946950.

    • Search Google Scholar
    • Export Citation
  • 4

    Gajra A, Newman N, Gamble G et al.. Impact of number of lymph nodes sampled on outcome in patients with stage I non-small cell lung cancer. J Clin Oncol 2003;21:10291034.

    • Search Google Scholar
    • Export Citation
  • 5

    Koppie TM, Vickers AJ, Vora K et al.. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 2006;107:23682374.

    • Search Google Scholar
    • Export Citation
  • 6

    American College of Surgeons Press Release: National Quality Forum Endorsed Commission on Cancer Measures for Quality of Cancer Care for Breast and Colorectal Cancers, April 12, 2007. Available at: http://facs.org/cancer/qualitymeasures.html. Accessed July 7, 2008.

    • Search Google Scholar
    • Export Citation
  • 7

    Wong SL, Hong J, Hollenbeck BK et al.. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298:21492154.

    • Search Google Scholar
    • Export Citation
  • 8

    Donohue JP, Thornhill JA, Foster RS et al.. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965–1989). J Urol 1995;153:8589.

    • Search Google Scholar
    • Export Citation
  • 9

    Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol 2004;22:225233.

    • Search Google Scholar
    • Export Citation
  • 10

    Fisher B, Anderson S, Bryant J et al.. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy with radiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:12331241.

    • Search Google Scholar
    • Export Citation
  • 11

    Dhar NB, Klein EA, Reuther AM et al.. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008;179:873878.

    • Search Google Scholar
    • Export Citation
  • 12

    Danielson H, Kokkola A, Kiviluoto T et al.. Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer. Scand J Surg 2007;96:3540.

    • Search Google Scholar
    • Export Citation
  • 13

    Yonemura Y, Wu CC, Fukushima N et al.. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 2006;53:389394.

    • Search Google Scholar
    • Export Citation
  • 14

    Bonenkamp JJ, Hermans J, Sasako M et al.. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999;340:908914.

    • Search Google Scholar
    • Export Citation
  • 15

    Hartgrink HH, van der Velde CJH, Putter H et al.. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004;22:20692077.

    • Search Google Scholar
    • Export Citation
  • 16

    LeVoyer TE, Sigurdson ER, Hanlon AL et al.. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of INT-0089. J Clin Oncol 2003;21:29122919.

    • Search Google Scholar
    • Export Citation
  • 17

    Herr HW, Faulkner JR, Grossman HB et al.. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004;22:27812789.

    • Search Google Scholar
    • Export Citation
  • 18

    Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131:7988.

  • 19

    Keller SM, Adak S, Wagner H et al.. Mediastinal lymph node dissection improves survival in patients with stage II and stage IIIa non-small cell lung cancer. Ann Thorac Surg 2000;70:358366.

    • Search Google Scholar
    • Export Citation
  • 20

    Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573578.

    • Search Google Scholar
    • Export Citation
  • 21

    Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastases of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg 2004;239:483490.

    • Search Google Scholar
    • Export Citation
  • 22

    Wu Y, Wang S, Huang Z. Extent of lymphadenectomy in stage I-IIIA non-small cell lung cancer: a randomized clinical trial. Zhonghua Zhong Liu Za Zhi 2001;23:4345.

    • Search Google Scholar
    • Export Citation
  • 23

    Izbicki JR, Passlick B, Patel K et al.. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer—results of a prospective randomized study. Ann Surg 1998;227:138144.

    • Search Google Scholar
    • Export Citation
  • 24

    Sugi K, Nawata K, Fujita N et al.. Systematic lymph node dissection for clinically diagnosed peripheral non-small cell cancer less than 2 cm in diameter. World J Surg 1998;22:290295.

    • Search Google Scholar
    • Export Citation
  • 25

    Pedrazzoli S, Di Carlo V, Dionigi R et al.. Standard versus extended lymphadenctomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter prospective randomized study. Ann Surg 1998;228:508517.

    • Search Google Scholar
    • Export Citation
  • 26

    Nimura Y, Nagino M, Kato H et al.. Regional versus extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer: a multicenter randomized controlled trial. HPB Surg 2004;6(Suppl 1):2.

    • Search Google Scholar
    • Export Citation
  • 27

    Farnell MB, Pearson RK, Starr MG et al.. A prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in respectable pancreatic head adenocarcinoma. Surgery 2005;138:618630.

    • Search Google Scholar
    • Export Citation
  • 28

    Riall TS, Cameron JL, Lillemoe KD et al.. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. J Gastrointest Surg 2005;9:11911206.

    • Search Google Scholar
    • Export Citation
  • 29

    Wong SL, Ji H, Hollenbeck BK et al.. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298:21492154.

    • Search Google Scholar
    • Export Citation
  • 30

    Sigurdson ER. Lymph node dissection: it is diagnostic or therapeutic? J Clin Oncol 2003;21:965967.

  • 31

    Wibe A, Eriksen MT, Syse A et al.. Total mesorectal excision for rectal cancer: what can be achieved by a national audit? Colorectal Dis 2003;5:471477.

    • Search Google Scholar
    • Export Citation
  • 32

    Birkmeyer JD. Understanding surgeon performance and improving patient outcomes. J Clin Oncol 2004;22:27652766.

  • 33

    Desch CE, McNiff KK, Schneider EC et al.. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008;26:36313637.

    • Search Google Scholar
    • Export Citation
  • 34

    Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:17651771.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 140 70 3
PDF Downloads 52 11 1
EPUB Downloads 0 0 0